Adding Mark News Today

Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making ...

Published: May 05, 2021 Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 20...